Display options
Cite
Janakiram M, Chinai JM, Zhao A, et al. HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families. Oncoimmunology. 2015;4(8):e1026534doi: 10.1080/2162402X.2015.1026534.
Janakiram, M., Chinai, J. M., Zhao, A., Sparano, J. A., & Zang, X. (2015). HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families. Oncoimmunology, 4(8), e1026534. https://doi.org/10.1080/2162402X.2015.1026534
Janakiram, Murali, et al. "HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families." Oncoimmunology vol. 4,8 (2015): e1026534. doi: https://doi.org/10.1080/2162402X.2015.1026534
Janakiram M, Chinai JM, Zhao A, Sparano JA, Zang X. HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families. Oncoimmunology. 2015 Apr 14;4(8):e1026534. doi: 10.1080/2162402X.2015.1026534. eCollection 2015 Aug. PMID: 26405587; PMCID: PMC4570140.
Copy Download .nbib Format: NLM
Share it on

Oncoimmunology. 2015 Apr 14;4(8):e1026534. doi: 10.1080/2162402X.2015.1026534. eCollection 2015 Aug.

HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families.

Oncoimmunology

Murali Janakiram, Jordan M Chinai, Aimin Zhao, Joseph A Sparano, Xingxing Zang

Affiliations

  1. Department of Microbiology and Immunology; Albert Einstein College of Medicine ; Bronx, NY USA ; Department of Oncology; Montefiore Medical Center; Albert Einstein College of Medicine ; Bronx, NY USA.
  2. Department of Microbiology and Immunology; Albert Einstein College of Medicine ; Bronx, NY USA.
  3. Department of Obstetrics and Gynecology; Renji Hospital; Shanghai Jiao Tong University School of Medicine ; Shanghai, China.
  4. Department of Oncology; Montefiore Medical Center; Albert Einstein College of Medicine ; Bronx, NY USA.

PMID: 26405587 PMCID: PMC4570140 DOI: 10.1080/2162402X.2015.1026534

Abstract

We and others recently discovered HHLA2 as a new B7 family member and transmembrane and immunoglobulin domain containing 2 (TMIGD2) as one of its receptors. Based on a new study we propose that HHLA2 may represent a novel immunosuppressive mechanism within the tumor microenvironment and hence could be a target for cancer therapy. TMIGD2 may be another therapeutic target.

Keywords: B7 family; CD28 family; HHLA2; TMIGD2; angiogenesis; immunosuppression; immunotherapy; ligand; receptor; tumor microenvironment

References

  1. Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5271-9 - PubMed
  2. Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9879-84 - PubMed
  3. Immunogenetics. 2012 Aug;64(8):571-90 - PubMed
  4. Nat Commun. 2013;4:2043 - PubMed
  5. Clin Cancer Res. 2015 May 15;21(10):2359-66 - PubMed
  6. Cancer Discov. 2012 May;2(5):401-4 - PubMed
  7. Genomics. 1999 Aug 1;59(3):255-63 - PubMed
  8. Trends Mol Med. 2015 Jan;21(1):24-33 - PubMed
  9. Mol Biol Cell. 2012 May;23(9):1646-56 - PubMed

Publication Types

Grant support